Health Care Technology
Company Overview of Omicia, Inc.
Omicia, Inc. develops scalable and integrated informatics systems to interpret human genome sequences for research and clinical applications. The company offers Opal, a cloud-based and software-as-a-service informatics platform that allows researchers to analyze genomes by prioritizing disease-causing variants and genes. Its solution enables researchers and clinical diagnostic organizations to identify the genetic basis of various conditions, including childhood diseases, cancer, and cardiovascular diseases. The company was incorporated in 2012 and is based in Oakland, California.
1625 Clay Street
Oakland, CA 94612
Founded in 2012
Key Executives for Omicia, Inc.
Chief Executive Officer and Director
Co-Founder and Chief Technology Officer
Chief Medical Officer and Member of Scientific Advisory Board
Compensation as of Fiscal Year 2014.
Omicia, Inc. Key Developments
Omicia Introduces Opal Clinical, Interpretation Software for NGS Diagnostics
Oct 16 14
Omicia, Inc. announced the commercial availability of Opal Clinical(TM), the company's software solution for diagnostic testing organizations. With the cost of next-generation sequencing rapidly decreasing, the time and effort required for interpretation is becoming the rate-limiting factor to making genomics a reality in the clinic. Opal Clinical is a comprehensive solution that addresses this bottleneck. With Opal Clinical, hospitals and diagnostic labs can launch NGS tests faster and interpret results more accurately and quickly. A scalable Software-as-a-Service (SaaS) solution, Opal Clinical was built for the new generation of genomic diagnostic tests. Omicia's comprehensive approach, including unique algorithms for interpreting vast amounts of NGS data, increases the accuracy and reduces the cost of interpretation. Omicia's Opal Clinical key features include: Support for targeted gene panels as well as whole exome or genome tests. Complete clinical interpretation workflow to speed turnaround time while ensuring comprehensiveness. Generation of lab-branded physician-ready clinical reports, as well as APIs for integration with LIMS and EHRs. Comprehensive variant curation within panels to accelerate patient interpretation. HIPAA and CLIA compliance.
Omicia, Inc. Taps Renowned Clinical and Genomics Experts for Scientific Advisory Board
Jun 25 14
Omicia, Inc. announced it has expanded its scientific advisory board (SAB). Four clinical and genomic scientists will advise the strategic development of Omicia's clinical diagnostic genome interpretation software, and support the company's vision of improved patient care through personalized medicine. The new members of Omicia's SAB represent expertise in both clinical and research aspects of genomics: Heidi Rehm, Ph.D., FACMG -- One of the Principal Investigators of a recent NIH-funded initiative called the ‘Clinical Genome Resource’; Director of the Laboratory for Molecular Medicine at Partners Healthcare Personalized Medicine and Associate Professor of Pathology at Harvard Medical School. Geoffrey Ginsburg, M.D., Ph.D. -- Pioneer in translational genomics and precision medicine with funding from the NIH, the US Air Force, the US Navy, DARPA and the Gates Foundation; Director, Genomic Medicine of the Duke Institute for Genome Sciences & Policy; and Executive Director of the Center for Personalized Medicine and Precision, Duke Medicine and Professor of Medicine and Biomedical Engineering. Thomas Quertermous, M.D. -- A renowned expert whose research focuses on the genetic basis of cardiovascular disease; William G. Irwin Professor of Medicine and Director of Research for the Division of Cardiovascular Medicine at Stanford University; senior author of recently-published JAMA paper on the current state of whole genome sequencing, interpretation and clinical practicality. Mark Yandell, Ph.D. -- Internationally recognized expert in comparative genomics and bioinformatics with roots in the early days of the Human Genome Project at Washington University and Celera Genomics; University of Utah H.A. & Edna Benning Presidential Endowed Chair Professor of Human Genetics, and Co-director of the USTAR Center for Genetic Discovery; collaborator and co-inventor of Omicia's VAAST and newly-released Phevor algorithms.
Omicia, Inc. Appoints Paul Billings as Chief Medical Officer and Scientific Advisory Board Member
May 18 14
Omicia, Inc. announced the appointment of Paul Billings, MD, PhD, FACP, FACMG as Chief Medical Officer (CMO) and will serve on Omicia's Scientific Advisory Board. Dr. Billings joins Omicia as genomics expands from the research lab to become a valuable clinical diagnostic tool. He joins Omicia's leadership as it drives forward the company's vision of individualized medicine enabled by robust genomic interpretation. The company noted that prior to joining Omicia, Dr. Billings was CMO at Life Technologies, acquired by Thermo Fisher Scientific, Inc.
Similar Private Companies By Industry
Recent Private Companies Transactions
January 7, 2014